VIM and triple-negative breast carcinoma: Studies have shown that vimentin enhances triple-negative breast cancer (TNBC) aggressiveness and resistance to chemotherapeutic agents, and withaferin A, an inhibitor of vimentin [211], could be a major player in combating drug resistance and the recurrence of TNBC [212].